OBJECTIVES: Prostate specific antigen (PSA) is a widely used and clinically valuable marker for prostate disease. In order to enable the development of new PSA assays and progress the understanding of the biology of PSA we have analyzed PSA in seminal plasma. DESIGN AND METHODS: PSA in seminal plasma from men attending a fertility clinic and healthy controls was analyzed using SDS-PAGE, Western blotting and mass spectrometry. RESULTS: Using mass spectrometry, different forms of PSA could be identified in 1-9 bands seen on SDS-PAGE analysis of the respective sample. However, a majority of these molecular forms of PSA were not observed on Western blots. Enzymatic activity of PSA isoforms was demonstrated by sequencing data in zymogram gels. Multivariate analysis of clinical data revealed well-separated patient groups. CONCLUSIONS: We demonstrated that PSA in seminal plasma occurs in several isoforms, yet not all were detectable using an antibody based clinical routine method. The heterogeneity of PSA expression might be of clinical significance, by an improved patient phenotyping.
OBJECTIVES:Prostate specific antigen (PSA) is a widely used and clinically valuable marker for prostate disease. In order to enable the development of new PSA assays and progress the understanding of the biology of PSA we have analyzed PSA in seminal plasma. DESIGN AND METHODS: PSA in seminal plasma from men attending a fertility clinic and healthy controls was analyzed using SDS-PAGE, Western blotting and mass spectrometry. RESULTS: Using mass spectrometry, different forms of PSA could be identified in 1-9 bands seen on SDS-PAGE analysis of the respective sample. However, a majority of these molecular forms of PSA were not observed on Western blots. Enzymatic activity of PSA isoforms was demonstrated by sequencing data in zymogram gels. Multivariate analysis of clinical data revealed well-separated patient groups. CONCLUSIONS: We demonstrated that PSA in seminal plasma occurs in several isoforms, yet not all were detectable using an antibody based clinical routine method. The heterogeneity of PSA expression might be of clinical significance, by an improved patient phenotyping.
Authors: M F Darson; A Pacelli; P Roche; H G Rittenhouse; R L Wolfert; M S Saeid; C Y Young; G G Klee; D J Tindall; D G Bostwick Journal: Urology Date: 1999-05 Impact factor: 2.649
Authors: S D Mikolajczyk; L S Grauer; L S Millar; T M Hill; A Kumar; H G Rittenhouse; R L Wolfert; M S Saedi Journal: Urology Date: 1997-11 Impact factor: 2.649
Authors: Glòria Tabarés; Catherine M Radcliffe; Sílvia Barrabés; Manel Ramírez; R Núria Aleixandre; Wolfgang Hoesel; Raymond A Dwek; Pauline M Rudd; Rosa Peracaula; Rafael de Llorens Journal: Glycobiology Date: 2005-09-21 Impact factor: 4.313
Authors: A Bélanger; H van Halbeek; H C Graves; K Grandbois; T A Stamey; L Huang; I Poppe; F Labrie Journal: Prostate Date: 1995-10 Impact factor: 4.104
Authors: Akos Végvári; Karin Sjödin; Melinda Rezeli; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga Journal: Mol Cell Proteomics Date: 2013-07-10 Impact factor: 5.911
Authors: Ali Ahmad Bayat; Roya Ghods; Mahdi Shabani; Ahmad Reza Mahmoudi; Omid Yeganeh; Hadi Hassannia; Ali Sadeghitabar; Leila Balay-Goli; Farzaneh Noutash-Haghighat; Ali Reza Sarrafzadeh; Mahmood Jeddi-Tehrani Journal: Avicenna J Med Biotechnol Date: 2015 Jan-Mar
Authors: Alba Fernandez-Encinas; Agustín García-Peiró; Javier Del Rey; Jordi Ribas-Maynou; Carlos Abad; Maria José Amengual; Elena Prada; Joaquima Navarro; Jordi Benet Journal: Int J Mol Sci Date: 2020-07-17 Impact factor: 5.923